ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Gene Vector Labs Seek Vector Producers

February 23, 1996

Van Nevel New NCI information Chief: Karel Leaves For Johnson Foundation

August 30, 1974

ASCO Recommends Beginning Palliative Care Alongside Standard Therapy in Metastatic NSCLC

February 24, 2012

NCI-Approved CTEP Trials For the Month of October

October 26, 2012

New Chairman Of Core Grant Review Committee Has Some Advice for Applicants

May 5, 1978

NCAB Accepts Plan for Organ Systems Program, Remains Split On Some Issues

February 11, 1983